Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective.


Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 18 02 2019
accepted: 14 01 2020
pubmed: 24 1 2020
medline: 18 3 2020
entrez: 24 1 2020
Statut: ppublish

Résumé

This current study retrospectively analyzed the clinical characteristics of 69 adult patients with acquired pure red cell aplasia (PRCA) including 40 elderly and 29 non-elderly patients from September 2009 to June 2019. The remission induction therapy regimens included cyclosporine A (CsA), corticosteroids (CS), or other immunosuppressive agents. The overall response rate was 55% (22/40) in the elderly group compared with 75.9% (22/29) in non-elderly patients (P = 0.075). In elderly patients, the best remission was achieved in the group treated with CsA than those treated with CS or other immunosuppressive agents (83.3% vs 26.7% vs 42.9%%, P = 0.004). However, outcomes of remission were similar among different treatment groups (P = 0.458) in non-elderly patients. CS induced a higher response rate in the non-elderly than that in the elderly (88.9% vs 26.7%, P = 0.009). By univariate and multivariate analysis, the clinical efficacy of elderly patients with acquired PRCA was closely associated with an induction regimen of CsA (P = 0.009; P = 0.017). In conclusion, CsA might produce higher response rate than CS and other drugs in elderly patients with acquired PRCA.

Identifiants

pubmed: 31970447
doi: 10.1007/s00277-020-03926-6
pii: 10.1007/s00277-020-03926-6
doi:

Substances chimiques

Cyclosporine 83HN0GTJ6D

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

443-449

Subventions

Organisme : State Administration of Traditional Chinese Medicine Industry Specialty
ID : No.201407001-4
Organisme : National Public Health Grand Research Foundation
ID : No.201202017
Organisme : Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute
ID : No. JX10231801
Organisme : Project Funded by Jiangsu Provincial Special Program of Medical Science
ID : No. BL2014086

Auteurs

Xiaoqing Liu (X)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Xingyu Lu (X)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Lang Chen (L)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Yan Yang (Y)

The First Affiliated Hospital of Jilin University, 71# Xinming Street, Changchun, 130021, Jilin Province, China.

Xuemei Wu (X)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Ruinan Lu (R)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Shuai Wang (S)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Jianfu Zhang (J)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Ming Hong (M)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Yu Zhu (Y)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Guangsheng He (G)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China. heguangsheng1972@sina.com.

Jianyong Li (J)

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, 300# Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH